This week’s episode dives into the biggest stories shaping Australia’s life sciences landscape — from global leadership milestones to biotech breakthroughs and policy reform.

We celebrate Professor Tony Lawler’s appointment as Global Chair of the International Coalition of Medicines Regulatory Authorities (ICMRA), marking Australia’s growing influence in global regulatory science.
In pharma, Takeda, Pfizer, and Boehringer Ingelheim make bold moves, while new funding under the Life Saving Drugs Program delivers long-awaited hope for rare disease patients.

The biotech sector surges ahead with the opening of Australia’s first Viral Vector Manufacturing Facility in Westmead and major international deals, including Novartis’s $18.4B acquisition of Avidity Biosciences.
Meanwhile, medtech innovation keeps pace as CSL Seqirus expands its global vaccine partnerships and Medicare boosts access to diagnostics.

Plus, we spotlight leadership shifts at AbbVie, Uniseed, and PolyNovo, and Nav Lee’s representation of ARCS on the world stage in Cairo.

🎧 Tune in for insights, context, and commentary on how these developments are shaping Australia’s clinical trials, biotech, and medtech future.